Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$3.57M+730.93%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ofer Gonen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 121
- Beta
- 0.14
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 2.35
Financials
Revenue
$3.57M+730.9%Net Income
$-5.99MEBITDA
$-8.16MFree Cash Flow
$-8.46MEPS (diluted)
$-0.46Shares Outstanding (diluted)
13.02M+316.5%Operating Expenses
$9.57MCash & Debt
$27.85MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.96M | $-23.88M | $-2.10 |
| 2024 | $20.22M | $-30.22M | $-3.03 |
| 2023 | $18.69M | $-6.72M | $-0.75 |
| 2022 | $26.50M | $-19.60M | $-3.93 |
| 2021 | $23.76M | $-13.55M | $-3.48 |
| 2020 | $21.76M | $-9.20M | $-2.38 |
| 2019 | $31.79M | $4.96M | $1.26 |
| 2018 | $3.40M | $-1.06M | $-0.28 |
| 2017 | $2.50M | $-22.15M | $-6.64 |
| 2016 | $1.56M | $-18.89M | $-6.05 |
| 2015 | $601.0K | $-22.09M | $-7.13 |
| 2014 | $259.0K | $-18.88M | $-6.65 |
| 2013 | $0.00 | $-15.35M | $-5.28 |
| 2012 | $0.00 | $10.94M | $3.76 |
Valuation
MDWDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (12)
- Newsglobenewswire.com·6d ago·Neutral
…l Phase III VALUE study, and the estimated $1.05 billion U.S. annual peak sales potential YAVNE, Israel, November 16, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, December 2, 2026, at 11:00 a.m.
View source ↗ - Newszacks.com·10d ago·Negative
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates MediWound (MDWD) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.24 per share a year ago.
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027
View source ↗ - Newszacks.com·17d ago·Neutral
MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last? MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - Newsglobenewswire.com·19d ago·Negative
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into an underwriting agreement with H.C.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
MediWound to Report Third Quarter 2026 Financial Results MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12 th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd.
View source ↗ - Newsglobenewswire.com·61d ago·Neutral
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid® MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ®
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
…ssessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the ongoing Phase III VALUE study evaluating the safety and efficacy of EscharEx® in patients with venous leg ulcers (V…
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd.
View source ↗ - Newsseekingalpha.com·101d ago·Positive
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·101d ago·Neutral
MediWound Q2 Earnings Call Highlights MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment.
View source ↗ - Newszacks.com·101d ago·Neutral
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates MediWound (MDWD) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.23 per share a year ago.
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.61 per share
Typical surprise +13.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.65 vs $-0.71beat
- Thu, Aug 13$-0.77 vs $-0.76miss
- Wed, May 27$-0.23 vs $-0.65beat
- Thu, Mar 5$-0.56 vs $-0.65beat
- Thu, Nov 20$-0.24 vs $-0.81beat
- Thu, Aug 14$-1.23 vs $-0.55miss
Estimates and results for MDWD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MDWD officers and directors.
- Bought
- $143k
- Sold
- $82k
7 trades
4 trades
- Rubinstein Samuelbought
- Rubinstein Samuelsold
- Hess Shmuelsold
- Hess Shmuelsold
- Hess Shmuelsold
- Shamir Nachumbought
- Shamir Nachumbought
- Fox David Mortonbought
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MDWD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
